Medical Digest & Congress Report

May 14 2024
Medical Digest & Congress Report Podcast artwork

The MedicalDigest.org / CongressReport.eu podcast covers the latest evidence based medical news from cardiology, hematology, oncology, diabetology, pulmonology, dermatology, urology and more. Made for healthcare professionals and researchers, we are an independent, open-access platform. CongressReport.eu portal enables HCPs to get acquainted with new clinical trial results, medical diagnostic and treatment guidelines. Our non-promotional website collects and stores the relevant scientific information, KOL insights, key lectures, poster presentations in a user-friendly format.

RSS feed Share
Copy RSS


Subscribe on Podcast Addict


HPV-associated head and neck cancers - report from Danube Symposium

May 14 2024 7 mins  
Professor Thomas Hoffmann, Director of the Department of Otolaryngology and Head and Neck Surgery at the University of Ulm, raises awareness of the growing number of HPV-associated head and neck cancers in our interview. The right combination of treatment modalities - less and less invasive surgical procedures, increasingly precise radiotherapy options and systemic therapies, espec

Breakthroughs and challenges in the treatment of head and neck cancer - report from Danube Symposium

May 14 2024 4 mins  
Dr. Robert Sifrer, Director of the Department of Otolaryngology and Head and Neck Surgery at the University of Ljubljana, believes that the most important breakthrough in the treatment of head and neck cancer patients has been the recent development of immunotherapy, which is also helping patients with advanced stage cancer, and expects the importance of drug therapies to increase

Featured Clinical Researches: acute coronary syndromes, atrial fibrillation related ablation procedures and aortic valve replacements - report from ACC2024

Apr 18 2024 9 mins  
Professor George D. Dangas chaired the Featured Clinical Research on Monday and shared his insights on the trials about acute coronary syndromes, atrial fibrillation related ablation procedures and aortic valve replacements. - Fractional Flow Reserve-guided Complete Or Culprit-only PCI In Patients With ST-elevation Myocardial Infarction - Intravascular Ultrasound-guided Versus Angi

Late-Breaking Clinical Trials on Cholesterol Management, Hypertension and Exercise - report from ACC2024

Apr 18 2024 8 mins  
Professor Andrew M. Kates shared his insights on Late-Breaking Clinical Trials II, presented during at ACC.24: - Zilebesiran In Combination With A Standard-of-care Antihypertensive In Patients With Inadequately Controlled Hypertension – Primary Results From The Phase 2 Kardia-2 Study - Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term

Late Breaking Clinical Trial on ACC - report from ACC2024

Apr 18 2024 8 mins  
Professor Athena Poppas shared his insights on the Late Breaking Clinical Trial sessions: - Effect Of Edetate Disodium Based Chelation Infusions On Cardiovascular Events In Post-MI Patients With Diabetes: The TACT2 Trial - Percutaneous Transvalvular Micro-axial Flow Pump In Infarct Related Cardiogenic Shock: Results Of The Danger-shock Trial - A Selective Aldose Reductase Inhibitor

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: the STEP-HFpEF and STEP-HFpEF DM randomised trials - report from ACC2024

Apr 17 2024 12 mins  
Professor Mikhail Kosiborod shared his insights onthe STEP-HFpEF and STEP-HFpEF DM randomised trials. Discussed studies: - Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials - Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes Vi

Late-Breaking Clinical Trials V - report from ACC2024

Apr 17 2024 7 mins  
ACC Immediate-Past President Edward T. A. Fry chaired the Late Breaking Clinical Trial V. and shared his insights on the trials: - Coronary Sinus Reducer For The Treatment Of Refractory Angina: A Randomised, Placebo-controlled Trial (ORBITA-COSMIC) - Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement In Patients At Low To Intermediate Risk: One Year Ou

Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials IV - report from ACC2024

Apr 17 2024 8 mins  
Professor Kathryn L. Berlacher shared his insights on Late-Breaking Clinical Trials IV, presented during at ACC.24: - Outcomes After Technology Assisted Nonprescription Rosuvastatin Administration: The TACTiC Trial - Preventing Cardiac Damage In Patients Treated For Breast Cancer And Lymphoma: A Phase 3 Randomized, Open Label, Blinded Endpoint, Superiority Trial Of Enalapril To Pre

Late Breaking Clinical Trial on interventional cardiology - report from ACC2024

Apr 17 2024 8 mins  
Professor Douglas E. Drachman shared his insights on the Late Breaking Clinical Trial sessions about interventional cardiology trials which he co-moderated. - Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement In Patients With Small Aortic Annuli: Primary Outcomes From The Randomized Smart Trial - Percutaneous Transvalvular Micro-axial Flow Pump In In

Lerodalcibep reduces LDL cholesterol by over 50% in high-risk patients - report from ACC2024

Apr 16 2024 21 mins  
Professor Eric Quinton Klug shared his insights on the LIBerate-HR trial. Among patients at high or very high risk for a heart attack or stroke, the addition of the investigational drug lerodalcibep to standard cholesterol-lowering medication for one year reduced LDL, or "bad" cholesterol, levels by more than half on average, compared with a placebo. In addition, 90% of p